Cycle
Developing hair follicles are surrounded by deep dermal vascular plexuses. Associated blood vessels function to supply nutrients to the developing follicle and foster waste elimination. As such, proper blood supply is necessary for effective hair follicle growth, further exemplified by the angiogenic properties of the anagen phase [ 90 ].
Theoretical benefits of increased blood flow to the hair follicles justifies the assessment of scalp massage on hair parameters. A 2016 study assessed the effect of a 4-min standardized daily scalp massage for 24 weeks among nine healthy men [ 91 ]. Authors found scalp massage to increase hair thickness, upregulate 2655 genes, and downregulate 2823 genes; hair cycle-related genes including NOGGIN, BMP4, SMAD4, and IL6ST were among those upregulated, and hair-loss related IL6 was among those downregulated. The authors thereby concluded that a standardized scalp massage and subsequent dermal papilla cellular stretching can increase hair thickness, mediated by changes in gene expression in dermal papilla cells [ 91 ].
In addition, of 327 survey respondents attempting standardized scalp massages following demonstration video, 68.9% reported hair loss stabilization or regrowth [ 92 ]. Positive associations existed between self-reported hair changes and estimated daily minutes, months, and total standardized scalp massage effort. This study is limited based on recall bias and reliance on patient adherence and technique, although it suggests promising therapeutic potential for standardized scalp massage, which functions to increase blood flow.
Similarly, minoxidil, a pharmacologic agent that relaxes blood vessels and increases blood flow, has been widely utilized for the management of AnA. While topical minoxidil has been FDA approved for MPAnA and FMPAnA, oral minoxidil, especially in a low dose, is used off-label for AA and TE [ 93 , 94 , 95 ].
In addition to the relaxation of blood vessels, minoxidil also acts as an anti-inflammatory agent, an inducer of the Wnt/β-catenin signaling pathway, and as an antiandrogen [ 96 ]. Effects on anagen and telogen phases have been proposed, although a study in rats found that topical minoxidil increased DNA synthesis rate in the anagen bulb, rather than prolonging the length of the anagen phase [ 97 ]. However, animal studies have described shortened telogen and increased telogen to anagen transition [ 98 ].
A comprehensive review of oral and topical minoxidil found that 2% topical minoxidil prompts hair regrowth in both frontotemporal and vertex areas among males with MPAnA, with peak hair regrowth after one year of use [ 96 ]. No significant differences were found between 2% and 5% topical solutions in terms of efficacy. A meta-analysis assessing topical minoxidil found an average score difference of 16.7 for the promotion of total hair growth between individuals receiving topical minoxidil vs. control (95% CI 9.34–24.03). An average difference of 20.9 (95% CI 9.07–32.74) was observed for non-vellus hair growth [ 99 ]. Similarly, individuals using minoxidil had a 2.28× greater likelihood of exhibiting hair growth than those using a placebo (95% CI 1.343–1.80).
In addition, despite off-label use, oral minoxidil 5 mg/day exhibited significantly greater efficacy than both 2% and 5% topical minoxidil in males with MPAnA [ 96 ]. Low dose oral minoxidil and sublingual may additionally be safe and effective in patients with FPAnA [ 96 ]. Interestingly, a review of 17 studies with 634 patients found oral minoxidil to be an effective strategy among patients refractory to topical formulations [ 100 ].
Despite minoxidil efficacy, authors have sought therapeutic strategies to maintain biological efficacy while reducing side effects, such as hypertrichosis. For example, a 2022 retroactive study of patients with minoxidil-induced hypertrichosis found clear improvement among 35 FPAnA patients following initiation or up-titration of oral bicalutamide, an antiandrogenic medication [ 101 ]. Simultaneous bicalutamide treatment at a mean dose of 14.4 mg allowed an increase in the mean daily minoxidil dose without the development of hypertrichosis.
In addition, authors have sought novel minoxidil delivery methods to maximize effects while minimizing side effects. A 2022 study used biocompatible and safe hyaluronic acid (HA)-constructed microneedles to deliver minoxidil to hair dermal papilla cells [ 102 ]. A chemotherapy-induced alopecia murine model was used to examine the effects of HA-microneedle delivery of minoxidil compared to conventionally applied minoxidil. HA solution alone demonstrated reduced hair loss in mice with alopecia. Yet, authors observed maximal anti-alopecia effects with minoxidil loaded HA-microneedles, measured via hair follicle length, hair density, and dermal thickness, although efficacy was comparable with topical minoxidil treatment [ 102 ]. Despite similar efficacy, microneedle delivery of minoxidil may maximize anti-alopecia effects while minimizing side effects during treatment.
Lastly, a 2022 study assessed the efficacy of liquid crystal nanocarriers to direct minoxidil to the pilosebaceous follicle, which is difficult to reach given its origination in deeper skin layers [ 103 ]. Authors loaded minoxidil into the liquid crystal nanocarrier and assessed biological effectiveness compared to conventionally applied minoxidil among rats. The crystal nanocarrier selectively targeted the pilosebaceous follicle, increasing efficacy and duration of biological effects while reducing side effects. Whereas untreated rats depicted a mean 3.6 mm regrowth and rats treated with hydro-alcoholic 5% w / v minoxidil showed a mean 4.3 mm regrowth after one month, rats treated with minoxidil-loaded nanocarriers demonstrated a significantly ( p < 0.001) greater mean re-growth (5.6 mm). The percentage of hair length increase was 19% and 59% for rats treated with hydro-alcoholic minoxidil and minoxidil-loaded nanocarriers, respectively. In addition, 12 healthy human volunteers demonstrated tolerability and safety of the nanocarrier via a safety evaluation characterized by treatment application on five ventral surfaces of each forearm [ 103 ]. This study suggests the liquid crystal nanocarrier is a safe and effective vehicle to delivery minoxidil selectively to the pilosebaceous follicle, allowing reduced concentrations of active compound to achieve greater biologic efficacy.
Hypoxia inducible factor (HIF) is a transcription factor that responds to hypoxic stress via angiogenesis regulation. As dermal papilla cells are reactive to hypoxia, HIF stimulation modulates neovascularization and regeneration, which is necessary to combat the lack of blood vessel and nutrient supply characteristic of AnA [ 104 ]. Thus, a 2023 study assessed the effect of HIF strengthening factor (HSF) hair restoration on various hair parameters [ 104 ]. Twenty subjects, four female and sixteen male, underwent a once-daily application of HSF hair restoration technology for nine months. Authors observed a 7.2% increase in hair thickness, 14.3% increase in hair density, and a 20.3% increase in shine and elasticity. Treatment-responsive subjects (85% of the cohort) depicted a 66.8% reduction in hair loss after six months of treatment, with an increase in hair growth up to 32.5% (mean 1.8%). Lastly, the test area depicted an average anagen hair percent increase of 8.0% and an average telogen hair percent decrease of −14.0%, depicting the ability of HSF hair restoration technology to promote telogen to anagen transition [ 104 ].
Herbs, supplements, prostaglandins, and light-based approaches have been shown to promote hair growth via direct stimulation of the hair follicle.
A review article conducted in 2019 summarized a variety of clinical trials that assessed the use of herbs for the treatment of hair loss [ 105 ]. The most evidence for promoting hair growth was attributed to many herbs including, “ Curcuma aeruginosa (pink and blue ginger), Serenoa repens (palmetto), Cucurbita pepo (pumpkin), Trifolium pratense (red clover), and Panax ginseng (Chinese red ginseng)” [ 105 ]. The article states that the beneficial effects on hair growth from these herbs is possibly due to their inhibitory effects on 5-alpha-reductase.
An additional review study, also conducted in 2019, summarized different alternative remedies for the treatment of alopecia [ 106 ]. Among the herbal treatments described, it was noted that Curcumin aeruginosa , when used in combination with minoxidil, can provide synergistic hair growth effects. Multiple studies summarized also supported the efficacy of topical melatonin, with results indicating that melatonin can increase hair counts, hair density, and anagen hair. Five studies also consistently supported the use of capsaicin for hair growth. One study described increased hair growth with oral supplementation and the remaining studies utilized topical capsaicin, which also displayed increases in hair growth.
Furthermore, Morbus alba , otherwise known as white mulberry, is an herb that has been shown to influence the hair growth cycle [ 107 ]. A study conducted in 2021 on hair follicle dermal papilla cells (HFDPCs) displayed promising results. Morbus alba was found to cause activation of beta-catenin in HFDPCs which subsequently caused activation of the anagen phase. This finding supports the potential use of Morbus alba as a possible treatment option for hair loss.
Bhrinjaraj, otherwise known as Eclipta alba , has also shown promising effects on hair growth. A study was conducted on male albino rats, and they received either topical Eclipta alba formulated into a 5% petroleum ether extract or the positive control, Minoxidil 2% [ 108 ]. The results showed that the treatment group with Eclipta alba had higher counts of hair follicles in the anagen phase compared to the control.
Additionally, quercetin, which is a component of Hottuyunia cordata extract, has also shown to have beneficial effects for hair growth. A study conducted in 2020 utilized human dermal papilla cells (hDPCs) to test the effects of the extract [ 109 ]. They found significant effects on the function of mitochondria. Specifically, the mitochondrial membrane potentials and NADPH production was found to be increased, suggesting enhanced mitochondrial function. Furthermore, Bcl2 expression increased which is a marker for the anagen phase and increases cell survival. The expressions of the following were also found to be increased: Ki67 (cell proliferation marker), various growth factors such as VEGF, bFGF, KGF, and phosphorylation of Akt, Erk, and CREB. The extract was found to increase hair shaft growth, specifically in cultured human hair follicles. Overall, the researchers attributed the increased hair growth to the activation of the MAPK/CREB pathway which led to the increased expression of growth factors due to quercetin application.
Another study testing quercetin in mouse models further supported the beneficial effects on hair growth [ 110 ]. Mice with alopecia areata were given either quercetin or placebo injections. The results showed that the mice receiving the quercetin injections had improved hair growth in lesioned areas whereas the placebo group did not. The researchers also utilized non-alopecic mice and heat-treated them to induce alopecia; placebo or quercetin injections were then provided. They found that none of the mice receiving quercetin injections developed alopecia, whereas 24% of the placebo group did develop alopecia. Thus, quercetin may be a viable treatment option for treating alopecia although additional studies in humans are warranted.
Rosemary oil is another herbal remedy that has been suggested to increase hair growth. A study conducted in 2015 recruited 60 patients and assigned them to either use topical minoxidil 2% or rosemary oil for 6 months. By the end of the study both groups displayed significant increases in hair counts ( p < 0.05) compared to baseline, although there was no significant difference between the two groups. Nevertheless, rosemary oil in this study showed comparable results to minoxidil. Interestingly, minoxidil also was observed to be more commonly associated with scalp itching ( p < 0.05) [ 111 ]. Lavender oil (LO) has also been tested as a hair growth remedy. A study conducted in 2016 with mouse models assessed 3% LO vs. 5% LO vs. 3% minoxidil applied topically on the backs of mice once a day, 5 days per week for 1 month. They found that hair follicles significantly increased in all 3 groups by the end of the study, however, they did not comment on the difference among the groups [ 112 ].
Proanthocyanins have also shown promising results for hair growth in the literature. A study conducted on mouse hair follicle cells found that proanthocyanins extracted from grape seeds caused a 230% increase in proliferation compared to the control vehicle. The authors attribute the hair growth effects to the proanthocyanins ability to increase transition from the telogen phase to the anagen phase [ 113 ]. Another study studied the effects of procyanidin B2 derived from apple extract. Thirty male subjects with male-pattern hair loss were recruited and instructed to apply either 1% procyanidin B-2 or placebo to the scalp twice daily for 6 months. Hair density at the end of the study was significantly higher in the treatment group ( p < 0.0001) [ 114 ].
Overall, there are many herbs that have been tested in the literature for their effectiveness in treating alopecia. Many of these trials have found promising results, and thus they provide another treatment modality for patients experiencing hair loss to utilize.
Supplements for hair growth have also been heavily researched for hair growth. In a randomized controlled trial conducted in 2018, 40 women with self-perceived hair thinning were recruited to either take the herbal supplement (brand: Nutrafol) or placebo for 6 months [ 115 ]. The supplement was noted to include a variety of ingredients including curcumin, ashwagandha, and saw palmetto. By days 90 and 180, the treatment group experienced a significant increase in the terminal and vellus hair counts compared to the placebo ( p < 0.009). Another supplement composed largely of marine protein (brand: Viviscal) were also tested in a separate randomized placebo-controlled trial [ 47 ]. Participants included 60 women with thinning hair and were asked to take either placebo or the supplement twice daily for 3 months. The results showed a significant increase in the terminal hair counts in the treatment group compared to placebo ( p < 0.0001).
Pumpkin seed oil supplements have also been shown to be beneficial for hair loss. A randomized control trial including 76 males with androgenetic alopecia were instructed to either take 450 mg of pumpkin seed oil supplements or placebo for 24 weeks [ 116 ]. Hair counts improved by 40% in those taking pumpkin seed oil whereas hair counts only improved 10% in the placebo group ( p < 0.001). The exact mechanism in the hair cycle is not known, however it is thought that pumpkin seed oil is enriched for delta-7-phytosterols and may inhibit 5-alpha-reductase activity [ 117 ].
Low level light therapy refers to therapeutic exposure to low levels of red and near infrared light [ 118 ]. Studies have demonstrated increased hair growth in mice with chemotherapy-induced alopecia and AA, in addition to both men and women human subjects. Proposed mechanisms of efficacy include stimulation of epidermal stem cells residing in the hair follicle bulge and promoting increased telogen to anagen phase transition [ 119 ]. Interestingly, while minoxidil and finasteride are the only FDA-approved drugs for AnA, a 2017 study found comparable efficacy among patients receiving low-level light therapy versus topical minoxidil among patients with FPAnA [ 120 ]. In addition, combination therapy resulted in the greatest patient satisfaction and lowest Ludwig classification scores of AnA.
A meta-analysis including eleven double-blinded randomized controlled trials found a significant increase in hair density among patients with AnA receiving low level light therapy compared to those in the placebo-controlled group; the standardized mean difference (SMD) was 1.316 (95% CI 0.993–1.639) [ 121 ]. Low level light therapy was effective for men and women. Furthermore, a subgroup analysis observed a more significant increase in hair growth in those receiving low-frequency therapy (SMD 1.555, 95% CI 1.132–1.978) than receiving high-frequency therapy (SMD 0.949, 95% 0.644–1.253) [ 121 ]. Despite the limitation of the heterogeneity of included trials, these results suggest low level light therapy to be a promising therapeutic strategy for AnA [ 121 ], although further research is necessary to determine the optimal wavelength and dosimetric parameters for hair growth [ 119 ].
Latanoprost is a prostaglandin F2 agonist and has been shown to have a direct effect on hair growth and pigmentation in eyelashes and hair around the eyes [ 122 ]. Clinically used to treat glaucoma, this medication was found to affect the follicles in the telogen phase and cause them to move to the anagen phase; this was supported by the increased number and length of eyelashes seen in patients using latanoprost [ 122 ]. Subsequently, the application of latanoprost for patients experiencing alopecia was assessed in clinical studies. One conducted in 2012 studied the effects of 0.1% latanoprost solution applied to the scalp for 24 weeks [ 123 ]. Participants included 16 males with mild androgenetic alopecia and were instructed to apply placebo on one area of the scalp and the treatment on another area. The results indicated that the area of scalp receiving latanoprost had significantly improved hair density compared to placebo ( p < 0.001).
Another prostaglandin known as bimatoprost, a prostamide-F2 analog, was also found to have a positive effect on hair growth in human and mouse models. A study conducted in 2013 also found that bimatoprost, in both humans and mice, stimulated the anagen phase of hair follicles prompting an increase in hair length, i.e., promoting hair growth [ 124 ]. The study also confirmed the presence of prostanoid receptors in human scalp hair follicles in vivo, opening the strong possibility that scalp follicles can also respond to bimatoprost in a similar fashion.
It is important to note, however, that not all prostaglandins induce hair growth. In a study analyzing individuals with androgenetic alopecia with a bald scalp versus a haired scalp, it was discovered that there was an elevated level of prostaglandin D2 synthase at the mRNA and protein levels in bald individuals [ 125 ]. They were also found to have an elevated level of prostaglandin D2. When analyzing the level of prostaglandin D2 synthase presence through the various phases of hair follicular growth, it was found that the level steadily increased throughout the anagen phase with a peak in late anagen, at the time of transition to the catagen (breakdown) phase. Therefore, the study concluded that PGD2’s hair loss effect represents a counterbalance to PGE2 and PGF2’s hair growth effects. In conclusion, prostaglandins are a promising treatment option for alopecia that require larger clinical studies; however, clinicians should be aware of which one to recommend for hair growth, as not all prostaglandins are alike.
Platelet rich plasma (PRP) has conventionally been used to supplement a patient’s endogenous platelet supply to promote increased healing. However, its prominent supply of growth factors has prompted assessment of PRP for alopecia. Growth factors promote hair growth and increase the telogen to anagen transition. For example, a murine study found the fibroblast growth factor (FGF) induced the anagen phase and subsequently promoted hair growth [ 126 ]. Growth factors prominently included in PRP include platelet-derived growth factor (PDGF), transforming growth factor β (TGF-β), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), insulin-like growth factor (IGF) and FGF [ 127 ].
The growth factors of platelet-rich plasma stimulate the development of new follicles and neovascularization [ 128 ]. Three meta-analyses have assessed the efficacy of PRP injections compared to placebo control on the number of hairs per cm 2 among patients with AnA. One meta-analysis involving 177 patients found a mean improvement of PRP treatment compared to placebo of 17.9 (95% CI 5.8–30.5, p = 0.004) [ 129 ]; a second meta-analysis with 262 AnA patients observed a mean difference of 38.8 (95% CI 22.22–55.28, p < 0.00001) [ 130 ]; and a third meta-analysis including studies with parallel or half-head design found a mean difference of 30.4 (95% CI 1.77–58.93, p < 0.00001) [ 131 ].
Despite the efficacious results described by each meta-analysis for the use in AnA, gender differences have been observed. A 2020 meta-analysis found that while PRP significantly increased hair density and hair diameter from baseline in men, PRP only increased hair diameter in women, in the absence of significantly increased hair density. Furthermore, hair density in men was only significantly increased by a double spin method, in contrast to a single spin method [ 132 ]. The authors conclude that PRP effectiveness may be improved via higher platelet concentrations. Ultimately, PRP injections appear to have clinical efficacy in early studies albeit slightly different effects in men vs. women. Future research is necessary to establish the optimal treatment protocol for both men and women with AnA. Also, the role of diet in the days prior to collection of the PRP has not been assessed in conjunction with hair, although diet influences the quality of the PRP [ 133 ].
4.1. ferritin.
Iron is a mineral that is integral for the body. It allows for humans to produce hemoglobin and myoglobin which are essential for the distribution of oxygen within the body. Additionally, iron plays a role in the production of certain hormones and allows for normal growth and development. Ferritin is a protein that allows for the intracellular storage of iron as, without it, iron intracellularly can produce free radicals which can damage cell machinery. Serum ferritin levels can be a marker for overall iron storage levels in the body [ 134 ]. Low serum ferritin levels have been supportive of an iron deficiency, anemia most commonly, however low levels can also be found in hypothyroidism and ascorbate deficiency [ 134 ].
Clinically, studies have suggested the correlation of low ferritin levels with hair loss. Although the mechanism of how low ferritin may lead to hair loss is not known, one theory highlights the importance of iron as a cofactor for ribonucleotide reductase, which is the rate limiting enzyme in DNA synthesis [ 135 ]. Since hair follicle cells are rapidly dividing, they require the constant use of ribonucleotide reductase and a deficiency of iron may limit the efficiency of this enzyme. In turn, this can lead to decreased cell turnover and regeneration leading to decreased hair growth. Thus, the evaluation in a patient presenting with hair loss has often involved an assessment of iron levels [ 135 ].
Several studies have investigated the relationship of low ferritin levels and hair loss. One study performed by Rasheed et al. evaluated 80 premenopausal women [ 66 ]. Females aged 18–45 years were included in the study. The serum ferritin levels were assessed in 80 women who had telogen effluvium (TE) or female-pattern hair loss (FPHL), and in 40 women with no hair loss. The average ferritin levels in women with TE was 14.7 μg/L and 23.9 μg/L in those with FPHL; the control group had average ferritin levels of 43.5 μg/L. The average ferritin levels in both types of hair loss were significantly lower when compared to controls ( p < 0.001). Another study conducted in 2022 explored ferritin levels in premenopausal and postmenopausal women with FPHL [ 136 ]. Statistically significant lower ferritin levels <70 μg/L were found only in premenopausal women with FPHL ( p = 0.01).
Furthermore, another study conducted in 2013 also found significantly low levels of ferritin only in premenopausal women with FPHL [ 137 ]. The average serum ferritin level in premenopausal women was 30.67 μg/L and this was compared to age/sex matched healthy controls who had an average ferritin level of 69.32 μg/L ( p < 0.001). Postmenopausal women, on the other hand, had an average ferritin level of 83.22 μg/L and when compared to their age/sex matched healthy controls who had an average ferritin of 85.38 μg/L, there was no statistically significant difference. Thus, overall, many studies seem to consistently highlight a more significantly lowered ferritin level in premenopausal women with FPHL. This may be explained by the fact that iron deficiency tends to be more common in premenopausal women due to monthly blood loss attributed to menstruation [ 138 ]. Although much less common, iron deficiencies can also occur in postmenopausal women due to malabsorption or gastrointestinal bleeding; however, there may be other factors contributing to their hair loss which can explain the lack of statistically significant changes in the ferritin level [ 135 ].
An important fact to highlight, however, is that it is difficult to conclude whether or not a low serum ferritin level is correlated to hair loss in postmenopausal women as most of the studies have been performed only with premenopausal women. Further investigation is required specifically in postmenopausal women with large sample sizes to better understand the role of ferritin in their hair loss.
Because the literature has widely highlighted the importance of ferritin levels in regards to hair loss, a few studies have been performed to determine if low ferritin levels are also significant in males experiencing hair loss. In the study described previously by Tahlawy et al., the researchers also assessed 30 males with androgenetic alopecia and compared their serum ferritin levels with 30 healthy males [ 66 ]. The results showed no statistically significant differences in ferritin levels in patients with androgenetic alopecia compared to controls. Furthermore, the study described previously by Park et al. also assessed ferritin levels in 97 males with male-pattern hair loss (MPHL). The average ferritin levels in males with MPHL was 132.3 μg/L which was significantly lower than the average found in controls, 210.2 μg/L ( p < 0.001); however, it is important to note that both of these levels are still considered to be in the normal serum ferritin range. As described previously, the women in this study did show an abnormally low average serum ferritin level in those with FPHL.
In general, based on the current studies it is challenging to make any conclusions regarding the involvement of ferritin in hair loss experienced by males. There are very few studies overall which have assessed ferritin levels in males with alopecia and, in the ones currently described, there seems to be no major significant correlation of ferritin levels to alopecia, especially when compared to the strong correlations found in women. Thus, further investigation is warranted to determine the importance of ferritin in males before clinicians can make any treatment recommendations.
Antinuclear antibody (ANA) is a common lab marker that tests for the presence of an antibody against material within the nucleus of the cell. Its most clinical value has been in the diagnosis of systemic lupus erythematosus; however, the marker has been found to be commonly positive in numerous other autoimmune diseases including polymyositis, dermatomyositis, Sjogren’s syndrome, rheumatoid arthritis, scleroderma, and mixed connective tissue disease. As a result, obtaining an ANA level is more often used as a supplement to making a diagnosis; the clinical signs and symptoms play a more integral role to correctly diagnosing which disease a patient may have since an ANA positive test could occur in a variety of diseases [ 139 ]. Importantly, a positive ANA is estimated to be prevalent in 25% of the population, including healthy individuals. Many studies have shown ANA positivity in individuals with no signs or symptoms of rheumatologic disease. Therefore, its utility has been extremely controversial.
The utility of obtaining ANA markers for patients presenting with hair loss is unclear. A retrospective study was conducted in 2015, with 49 women and 56 men presenting with pattern hair loss [ 140 ]. The researchers found the ANA to be positive in 19.1% of the women and 11.3% of the men, with a total of 30.4% ANA positivity. Thus, the ANA was found to be significantly more positive in women ( p < 0.05). When comparing the severity of hair loss using the BASP classification, there were no statistically significant differences among those with a positive ANA and those with a negative one. Additionally, there was no significant difference in average hair density or hair shaft diameter between ANA positive and negative patients. Thus, although many patients were found to incidentally have a positive ANA, it is unclear whether that has any correlation to their hair loss.
In general, obtaining ANA lab markers should currently be limited only to those patients with a high clinical suspicion of having a rheumatologic or autoimmune disease [ 141 ]. Additional studies must be performed with larger sample sizes of various types of alopecia to obtain a better understanding of its role and importance. Based on the current literature, since ANA positivity seems to be relatively prevalent in the population, a positive test in an otherwise asymptomatic person may have low clinical utility [ 139 , 142 ].
Rapid plasma reagin (RPR) is a test that can be utilized to diagnose syphilis, a sexually transmitted infection caused by Treponema pallidum bacteria [ 143 ]. There are many stages during the infection that each present with specific symptoms. These include primary-, secondary-, and tertiary-stage syphilis. Of importance to hair loss is the secondary stage. Syphilitic alopecia (SA) is defined by the occurrence of diffuse or patchy hair loss and often has been described as having a “moth-eaten” appearance [ 144 ]. Interestingly, SA can mimic various other forms of alopecia including telogen effluvium and alopecia areata [ 145 ]. As a result, it may be easy to miss a diagnosis of syphilis if the patient has not experienced other typical symptoms of syphilis. The literature has described cases where the only clinical manifestation has been hair loss [ 145 ]. As a result, it will be important for clinicians to also consider a sexual history from patients presenting with hair loss and include RPR testing in the work-up if that seems appropriate.
One of the known presenting symptoms of hypothyroid and hyperthyroidism is hair loss. There are thyroid hormone receptors present in human skin cells, therefore any alterations in the quantity of thyroxine or triiodothyronine will lead to an alteration in human skin and hair follicles [ 28 ]. In a study analyzing how T3 and T4 directly influence human hair follicles in vitro, it was found that both T3 and T4 have an inhibitory effect on the apoptosis of human hair matrix keratinocyte cells, while T4 was also found to have a significant stimulatory effect on their proliferation [ 146 ]. T3 was not found to have a significant stimulatory effect on the keratinocytes. Furthermore, the study found that increased levels of thyroid hormones had a direct correlation with increased numbers of anagenic hair follicles, and a decrease in catagenic hair follicles. Finally, T3 and T4 were also both found to have a stimulatory effect on hair follicle pigmentation. Overall, the study concluded that both T3 and T4 alter key parameters in human hair follicle growth and support the claim that the deficiency of thyroid hormones in hypothyroid individuals directly plays a role in the symptomatic hair loss.
4.5.1. diurnal cortisol slope testing.
Diurnal cortisol slope testing is a functional lab test that assesses the change in cortisol levels throughout one day. Cortisol is the main glucocorticoid hormone released in response to both acute and chronic stress. It has numerous effects on the body including immune function suppression, activation of the sympathetic nervous system, and alter glucose homeostasis [ 147 ]. Although acutely these effects allow the body to adequately function, chronically these changes can be detrimental and lead to inflammation, fatigue, and psychological maladaptation [ 148 ].
Cortisol levels can be assessed through saliva sample collections that a patient collects through the course of one day. A normal diurnal cortisol rhythm follows a distinct pattern throughout the day. As outlined by Adam et al., the first sample taken is to assess the waking cortisol, which is defined as the level established immediately upon awakening in the morning; this level is normally high [ 149 ]. The next sample is taken 30–40 min after waking up and is called the cortisol awakening response; this level will normally display a surge compared to the waking cortisol. The remainder of samples are collected at varying time points in the day, but overall should display a decline with the lowest levels recorded near bedtime. Overall, these cortisol levels can be used to generate a diurnal cortisol slope. Any changes or flattening in the curve of the slope can indicate abnormal cortisol production. Studies have shown that abnormal cortisol rhythms throughout the day can be associated with numerous negative health outcomes and an imbalance of the hypothalamic pituitary adrenal axis (HPA) [ 149 ]. However, this has not been studied specifically in relation to hair loss or hair thinning. Thus, diurnal cortisol slope testing may be beneficial to determine if abnormal cortisol rhythms are contributing to hair loss, as part of future studies.
A novel method to assess the function of the HPA axis and cortisol levels is to obtain hair cortisol levels. This method requires obtaining a strand of hair which is then ground or minced to extract cortisol levels [ 150 ]. Interestingly, this method to assess cortisol levels provides a few key differences from the traditional diurnal cortisol slope testing. First, hair cortisol levels do not provide an acute snapshot of cortisol activity much like the traditional diurnal cortisol slope testing provides, but rather it offers a retrospective look into the history of what cortisol levels have been like in the body. On average, since hair grows at a rate of 1 cm/month, the literature has outlined that the most proximal 1 cm of a hair strand to the scalp provides information about the cortisol activity in the last month [ 151 ]. The second centimeter of hair provides information about 2 months prior and the next centimeter provides details about 3 months prior and so on. The hair cortisol levels are considered reliable up to 6 cm from the scalp. Additionally, since this method only requires the extraction of hair strands, it could be more reliable than traditional cortisol testing which is highly dependent on patient compliance to be accurate [ 151 ].
One major drawback of hair cortisol testing and its correlation to hair loss is that there have not been many studies that have included it in their methodology for assessing hair loss, specifically. The current literature is limited to only highlighting, thus far, that hair cortisol testing is a reliable biomarker indicating that the body is undergoing chronic stress [ 152 ]. However, no conclusions can be made from that information regarding its utility in hair loss.
Current studies have focused on testing hair cortisol in rhesus macaques, a species of monkey, experiencing alopecia. A study conducted in 2014 with 99 rhesus macaques monkey’s divided them into two groups [ 153 ]. The alopecia group included monkeys with 30% or more hair loss and the control group included monkeys with less than 5% hair loss. Hair cortisol levels were analyzed in both groups and results showed that the alopecia group had increased concentrations of hair cortisol compared to the control group. Although this study provides a foundation for the incorporation of hair cortisol as a tool for understanding hair loss, further research is still warranted, especially in humans. Overall, it is too early to determine if hair cortisol testing may be beneficial in the work-up for patients presenting with hair loss.
Thyroid impact on mitochondrial function.
Thyroid hormones are major regulators of energy expenditure within the body and are responsible for establishing a basal metabolic rate. Mitochondria are the primary organelles in cells that are involved in energy production. Thus, thyroid hormones have been widely supported by the literature as having a role in regulating mitochondrial function [ 154 ]. Many studies have suggested that thyroid hormones alter the levels of mitochondrial oxygen consumption and subsequently ATP production. Specifically, in studies investigating the effects of hyperthyroidism on mitochondria, it was collectively found that mitochondrial oxygen consumption rates were increased along with ATP production rates [ 155 ].
Interestingly, a study conducted in 2014 investigated the impact of thyroid hormones on mitochondria present in hair follicles [ 154 ]. The study utilized organ cultured human scalp hair follicles and subjected them to TSH, T3, and T4 hormones. All of the thyroid hormones were found to increase gene and protein expression of “mitochondrial-encoded subunit 1 of cytochrome c oxidase (MTCO1), a subunit of respiratory chain complex IV, mitochondrial transcription factor A (TFAM), and Porin”. Additionally, complex 1, complex 4, and mitochondrial biogenesis were each upregulated. Furthermore, the study also found that T3 and T4 hormones both decreased reactive oxygen species (ROS) production. This finding is clinically important as high levels of ROS production have been correlated to contributing to a variety of dermatologic conditions. Thus overall, this study highlights the impact of thyroid hormones on mitochondrial energetic dynamics in hair follicles. Clinically, this is important because an imbalance in the hormones could contribute to hair loss. Thus, evaluating thyroid hormones in individuals presenting with hair loss may be useful.
Several studies have highlighted the effects of mitochondrial dysfunction on hair [ 156 , 157 ]. The mitochondria is the site of action for major biochemical reactions, including the electron transport chain and the Krebs cycle. In a study performed by Singh et al., mice with depleted mtDNA were found to have profound hair loss suggesting the importance of mitochondrial integrity [ 156 ]. Additionally, a study performed with epidermal specific Crif1 knockout mice found that the hair cycle was significantly reduced [ 158 ]. Crif1 is a mitochondrial protein responsible for the placement of oxidative phosphorylation (OXPHOS) polypeptides in the inner membrane of mitochondria. Furthermore, as discussed previously, the trial conducted by Kim et al. showed that quercetin improved mitochondria function which led to improved hair growth in cultured hair follicles [ 109 ]. Specifically, they noted increased cell proliferation markers, growth factors, increased MAPK/CREB signaling, increased NADPH production and increased mitochondrial membrane potentials, which collectively contributed to the improved hair growth noted in cultured hair follicles after supplementation with quercitrin. Thus, this study further supports the integral role of healthy mitochondrial function in the maintenance of normal hair growth.
As a result, assessing mitochondrial function may be clinically useful for determining its level of contribution to hair loss a patient may be experiencing. One method for testing the function of mitochondria is via organic acid profile testing (OAPT). The OAPT utilizes urine samples from patients to evaluate many different metabolites that can be indicators for how well the Krebs Cycle and electron transport chain (ETC) are functioning, since each of these reactions produce various byproducts [ 159 ]. Although organic acid testing is widely available in the functional medicine space, there are a dearth of studies that correlate it to hair loss or hair thinning. Therefore, given its widespread use within functional medicine, a formal clinical study on the utility of organic acid testing and hair loss should be conducted.
Hair growth is mediated by a complex cycle consisting of anagen, catagen, telogen, and exogen. A variety of factors impact the hair cycle, inducing anagen to telogen transition or vice vera. Inflammation has been shown to foster anagen to telogen transition and mediate a variety of hair loss subtypes via proinflammatory substance P regulation. Thyroid hormones and dihydrotestosterone exhibit regulation of the hair cycle, and research has suggested the ratio of estrogen to testosterone may be more clinically relevant than the serum levels of either hormone in isolation. While vitamin and mineral deficiency has been associated with sparse hair and alopecia, there is limited evidence to suggest supplementation in healthy subjects is beneficial. Poor sleep and cell division inhibiting medications, including various chemotherapies, negatively impact the hair cycle and contribute to loss. Conversely, increased blood flow, direct stimulation of the hair follicle, and growth factors promote telogen to anagen transition and hair growth. Specific therapies can include scalp massage, minoxidil, herbs, supplements, low level light therapy, prostaglandins, and platelet-rich plasma. Evidence is promising for the therapeutic success of many such modalities, although limitations commonly include poor study design with small sample sizes and inconsistent therapeutic protocols. A variety of diagnostic tests can be employed to determine contributing factors of hair loss. Useful testing includes serum ferritin and thyroid hormone panels. Diurnal cortisol slope testing may assess the balance of the HPA axis and the influence of stress while OAPT testing may help assess mitochondrial function in a healthy patient. ANA lab markers should only be ordered if there is suspicion for ongoing autoimmunity. There is inadequate evidence to currently suggest utility of obtaining hair cortisol levels. Ultimately, the numerous factors impacting the hair cycle necessitate a holistic and individualized approach.
AA: | Alopecia areata |
AnA: | Androgenetic alopecia |
CI: | Confidence interval |
CRY: | Circadian regulator gene |
DHEAS: | Dehydroepiandrosterone sulfate |
DHT: | Dihydrotestosterone |
FGF: | Fibroblast growth factor |
FPAnA: | Female-pattern androgenetic alopecia |
FSH: | Follicle-stimulating hormone |
Ig: | Immunoglobulin |
LH: | Luteinizing hormone |
LO: | Lavender oil |
MPAnA: | Male-pattern androgenetic alopecia |
OR: | Odds ratio |
PRP: | Platelet rich plasma |
PSQI: | Pittsburgh Sleep Quality Index |
SHBG: | Sex hormone binding globulin |
SMD: | Standardized mean difference |
TE: | Telogen Effluvium |
TSH: | Thyroid-stimulating hormone |
VDR: | Vitamin D receptor |
ROS: | Reactive oxygen species |
ETC: | Electron transport chain |
OAT: | Organic Acid Testing |
HA: | Hyaluronic acid |
HIF: | Hypoxia inducible factor |
HSF: | HIF strengthening factor |
HPA: | Hypothalamic pituitary adrenal axis |
SA: | Syphilitic alopecia |
PER: | Period gene |
RPR: | Rapid plasma reagin |
ANA: | Antinuclear antibody |
MPHL: | Male-pattern hair loss |
FPHL: | Female-pattern hair loss |
IGF: | Insulin-like growth factor |
This research received no external funding.
R.K.S. conceptualized the original idea, provided substantial revisions, and supervised the project. N.N. led manuscript writing with contribution from N.G. All authors provided critical feedback, have approved the submitted manuscript, and agree to be personally accountable for their own contributions and for ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated, resolved, and documented in the literature. All authors have read and agreed to the published version of the manuscript.
Not applicable.
Conflicts of interest.
The authors declare no conflict of interest.
R.K.S. serves as a scientific advisor for LearnHealth, Codex Labs, and Arbonne and as a consultant to Burt’s Bees, Novozymes, Nutrafol, Novartis, Bristol Myers Squibb, Abbvie, Leo, Biogena, UCB, Incyte, Sanofi, Novartis, Sun, and Regeneron Pharmaceuticals. The remaining authors report no disclosures.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
IMAGES
COMMENTS
Caption: Researchers developed a potential new treatment for alopecia areata, an autoimmune disorder that causes hair loss. The new microneedle patch delivers immune-regulating molecules that can teach T cells not to attack hair follicles, helping hair regrow. Pictured is an up-close view of the microneedles.
The research, which was recently published in the journal Developmental Cell, uncovered the precise mechanism by which the dermal papilla cells, specialized signal-producing fibroblasts found at the bottom of each hair follicle, encourage new development. Although the critical role dermal papilla cells play in regulating hair growth is widely ...
The study showed that molecules osteopontin and CD44 play a key role in this process, potentially opening new avenues for therapies for common hair loss conditions. The process by which aged, or senescent, pigment-making cells in the skin cause significant growth of hair inside skin moles, called nevi, has been identified by a research team led ...
Microneedling was performed on half the scalp treated with growth factors and the other half treated with normal saline. At 5 weeks, the microneedling with growth factor-treated scalp had an increase in hair count (52.91 ± 10.85) compared with the microneedling with saline-treated scalp (45.91 ± 9.98) ( P = 0.0001).
On June 23, the FDA announced its approval for the use of ritlecitinib — a Janus kinase (JAK) inhibitor — to treat alopecia areata in both adolescents and adults. The medicine, taken orally, goes by the product name Litfulo. Alopecia areata is an autoimmune disease characterized by sudden, often disfiguring, loss of hair.
Date: May 9, 2024. Source: Massachusetts Institute of Technology. Summary: Researchers developed a potential new treatment for alopecia areata, an autoimmune disorder that causes hair loss. The ...
Irvine, Calif., June 21, 2023 — The process by which aged, or senescent, pigment-making cells in the skin cause significant growth of hair inside skin moles, called nevi, has been identified by a research team led by the University of California, Irvine.The discovery may offer a road map for an entirely new generation of molecular therapies for androgenetic alopecia, a common form of hair ...
Aug. 1, 2022, 10:25 AM PDT / Source: TODAY. By Linda Carroll. A single molecule may hold the key to battling male- and female-pattern hair loss, recent research suggests. In mouse experiments ...
Recent articles in this series have focused on scientific evidence relating to hair growth and new insights into the pathogenesis and mechanism of hair loss. This article reviews emerging evidence that has advanced our understanding of hair growth in both of these areas to provide a context for outlining current and emerging therapies. These ...
Irvine, Calif., June 30, 2022 — University of California, Irvine-led researchers have discovered that a signaling molecule called SCUBE3 potently stimulates hair growth and may offer a therapeutic treatment for androgenetic alopecia, a common form of hair loss in both women and men. The study, published online today in Developmental Cell, determined the precise mechanism by which the dermal ...
More research on the effectiveness of treating hair loss with microRNA is needed in humans. A promising new treatment for hair loss may be on the horizon, according to researchers. A recent study ...
Growing New Hair Follicles in a Dish. In a second study, aimed at using stem cells for hair growth, the Columbia researchers have created a way to grow human hair in a dish, which could open up hair restoration surgery to more people, including women, and improve the way pharmaceutical companies search for new hair growth drugs.
A mouse model with hyperactivated dermal papilla cells and excessive hair, which will facilitate more discoveries about hair growth regulation, was developed for this research.
Galina Zhigalova/500px/Getty Images. New research has allowed scientists to generate new hair follicles — those tube-shaped pores that hug the strand and root of a hair — in vitro in a lab. It ...
New Scientist sifts the facts from the fiction. It takes about 50 to 70 days to culture a stem cell into a small patch of skin with hair. The skin forms in a bulb-like shape, about 4 millimetres ...
Hair-raising research: Scientists find surprising link between immune system, hair growth. ScienceDaily . Retrieved August 13, 2024 from www.sciencedaily.com / releases / 2022 / 06 / 220623110948.htm
Prunus mira Koehne (PK) is a wild peach species that contains various nutrients and fatty acids [ 152 ]. Zhou et al., showed the hair-promoting effect of nut oil from PK [ 42 ]. They demonstrated that nut oil from PK increased hair length in mice and upregulated Wnt10B, β-catenin, and GSK-3β expression in mice [ 42 ].
Abstract. Stem cells are being investigated in applications in male pattern baldness and other forms of alopecia of the human scalp. This report explores the literature regarding the various applications of stem cells and their potential for future use in the correction of multifactorial etiologies for male or female pattern baldness.
A major discovery in hair growth research could pave the way for future medications, a San Diego biopharmaceutical company has announced. (iStock) Maksim Plikus, PhD, Amplifica's chief scientific ...
Biotin is a popular ingredient for hair growth, but it may not be the most effective. We spoke with experts about whether biotin works for hair loss and the best hair growth products to use.
Research into the gene FGF5, which regulates hair length and plays a role in the transition from the anagen to the telogen phase, has shown that inhibiting the gene may extend the anagen phase of hair growth, but there are no Food and Drug Administration (FDA)-approved treatments using this approach at this time.
The best way to tell if you're losing more hair than the average is with a "pull test," says Dr. Kopelman. To do this, run your hand through a clean, dry section of your hair (about 40-60 strands), tugging gently at the ends. Dr. Kopelman says it may indicate underlying medical conditions or a hormone issue if more than four hairs fall out after a pass.
Horsetail contains silica (silicon dioxide), which research suggests can improve hair growth in women with temporary thinning hair. This study involved taking oral silicon tablets twice a day for 90 days. ... Some may help strengthen hair, slow hair loss, or promote new growth, but they're not likely to grow a full head of hair. And what works ...
Over 80% of men and almost 50% of women experience significant hair loss at some point in their life, according to NYU Langone Health. Enter, the vitamin and supplement industry, which advertises ...
Nioxin's System Kits rely on peppermint oil, niacinamide and biotin to thicken hair and is a favorite among Green's patients. The kits, which include a therapeutic shampoo, conditioner and ...
Vitamin D deficiencies can lead to hair loss conditions like alopecia, female pattern hair loss and excessive shedding. You'll find these depletions more in people aged 65 and over.
Sep. 22, 2023 — A receding hairline, a total loss of hair from the crown, and ultimately, the classical horseshoe-shaped pattern of baldness: Previous research into male pattern hair loss, also ...
Viviscal Man Hair Growth Supplements feature a proprietary, marine-based complex called AminoMar®, and it's been clinically proven to nourish thinning hair, promote new growth, and strengthen ...
Authors observed a 7.2% increase in hair thickness, 14.3% increase in hair density, and a 20.3% increase in shine and elasticity. Treatment-responsive subjects (85% of the cohort) depicted a 66.8% reduction in hair loss after six months of treatment, with an increase in hair growth up to 32.5% (mean 1.8%).
Newark, Aug. 07, 2024 (GLOBE NEWSWIRE) -- As per the report published by The Brainy Insights, the global hair transplant market is expected to grow from USD 12.42 Billion in 2023 to USD 47.49 ...